Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Priority Review to Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

July 24th 2025

Tabelecleucel earned FDA priority review for EBV-positive post-transplant lymphoproliferative disease following a January 2025 complete response letter.

IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML

July 24th 2025

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.

Factors for Selecting Iptacopan in C5 Inhibitor–Naive and –Exposed PNH

July 23rd 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, detail factors for selecting iptacopan in C5 inhibitor–naive and –exposed PNH.

Natural Language Processing Streamlines Clinical Encounter Note Collection in Indolent Systemic Mastocytosis

July 23rd 2025

Natural language processing models could help streamline processes within clinical settings.

Dr Luminari on the Safety Profile of Odronextamab in Relapsed/Refractory Follicular Lymphoma

July 22nd 2025

Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.

Oral Decitabine-Cedazuridine Is a Game Changer for MDS and CMML Treatment

July 22nd 2025

The oral formulation of decitabine-cedazuridine helps empower patients with MDS or CMML to maintain their quality of life from the comfort of their home.

European Commission Approves Obe-Cel for Adult R/R B-Cell Precursor Acute Lymphoblastic Leukemia

July 21st 2025

The European Commission approved obe-cel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

July 18th 2025

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

FDA Grants Orphan Drug Designation to ICT01 for Acute Myeloid Leukemia

July 18th 2025

ICT01 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD

July 16th 2025

Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.

Data for Iptacopan in PNH After Switching Anti-C5 Therapy: The APPULSE-PNH Trial

July 16th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on data for iptacopan in PNH after switching anti-C5 therapy.

Tambiciclib Plus Azacitidine and Venetoclax Elicits Robust Antitumor Activity in R/R AML

July 15th 2025

Tambiciclib plus azacitidine and venetoclax generated favorable ORR, OS, and safety outcomes in patients with relapsed/refractory acute myeloid leukemia.

New Approaches Combat GVHD and Improve Transplantation Outcomes in Hematologic Malignancies

July 15th 2025

In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.

ELM-2 Data Display Long-Term Efficacy and Safety of Odronextamab in R/R Follicular Lymphoma

July 15th 2025

Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.

FELIX Analysis Highlights Factors Associated With Sustained Remission With Obe-Cel in R/R Acute Lymphoblastic Leukemia

July 14th 2025

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

Molecular Insights Guide First-Line and Post-Transplant Strategies in AML

July 14th 2025

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

July 14th 2025

The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Dr Danilov on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in DLBCL

July 11th 2025

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.